- In January 2025, Novartis received expanded FDA approval for secukinumab in adult nr-axSpA patients with inadequate response to NSAIDs. This approval supports broader use of IL-17 inhibitors in early inflammatory arthritis management
- In October 2024, UCB launched a digital therapeutic platform for remote patient monitoring in axial spondyloarthritis. The platform enhances real-time data collection and supports treatment optimization for biologic users
- In August 2024, AbbVie published long-term safety results of its adalimumab biosimilar in nr-axSpA, reaffirming its sustained efficacy and safety profile for patients undergoing chronic treatment
- In March 2024, Eli Lilly initiated a global Phase IV study comparing ixekizumab and NSAIDs in biologic-naive nr-axSpA patients, aiming to establish evidence-based pathways for first-line therapy selection
- In December 2023, Amgen partnered with academic centers across Europe to expand real-world evidence generation for its biosimilar etanercept in non-radiographic populations, focusing on adherence and quality-of-life outcomes
- In September 2023, Pfizer launched a new support program in Asia-Pacific to enhance patient access and adherence for tofacitinib, offering digital onboarding and consultation support for nr-axSpA patients
